T2 BIOSYSTEMS INC (TTOO)
US89853L3024 - Common Stock
Overall TTOO gets a fundamental rating of 1 out of 10. We evaluated TTOO against 565 industry peers in the Biotechnology industry. TTOO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TTOO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TTOO had negative earnings in the past year.
TTOO had a negative operating cash flow in the past year.
TTOO had negative earnings in each of the past 5 years.
TTOO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -222.19%, TTOO is doing worse than 91.80% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -222.19% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-135.6%
ROA(5y)-134.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TTOO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TTOO does not have a ROIC to compare to the WACC, probably because it is not profitable.
TTOO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TTOO has more shares outstanding
The debt/assets ratio for TTOO has been reduced compared to a year ago.
2.2 Solvency
TTOO has an Altman-Z score of -45.56. This is a bad value and indicates that TTOO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -45.56, TTOO is not doing good in the industry: 93.40% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -45.56 |
ROIC/WACCN/A
WACC8.11%
2.3 Liquidity
A Current Ratio of 0.60 indicates that TTOO may have some problems paying its short term obligations.
With a Current ratio value of 0.60, TTOO is not doing good in the industry: 92.69% of the companies in the same industry are doing better.
TTOO has a Quick Ratio of 0.60. This is a bad value and indicates that TTOO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.36, TTOO is not doing good in the industry: 95.19% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.36 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 98.14% over the past year.
The Revenue for TTOO has decreased by -45.73% in the past year. This is quite bad
Measured over the past years, TTOO shows a decrease in Revenue. The Revenue has been decreasing by -7.29% on average per year.
EPS 1Y (TTM)98.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.75%
Revenue 1Y (TTM)-45.73%
Revenue growth 3Y-26.52%
Revenue growth 5Y-7.29%
Sales Q2Q%-0.61%
3.2 Future
The Earnings Per Share is expected to grow by 14.64% on average over the next years. This is quite good.
The Revenue is expected to grow by 54.19% on average over the next years. This is a very strong growth
EPS Next Y83.26%
EPS Next 2Y39.13%
EPS Next 3Y25.19%
EPS Next 5Y14.64%
Revenue Next Year51.43%
Revenue Next 2Y81.66%
Revenue Next 3Y68.18%
Revenue Next 5Y54.19%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TTOO. In the last year negative earnings were reported.
Also next year TTOO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TTOO's earnings are expected to grow with 25.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.13%
EPS Next 3Y25.19%
5. Dividend
5.1 Amount
No dividends for TTOO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
T2 BIOSYSTEMS INC
NASDAQ:TTOO (11/21/2024, 10:19:28 AM)
0.4511
-0.01 (-2.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.89M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -222.19% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.36 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)98.14%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y83.26%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-45.73%
Revenue growth 3Y-26.52%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y